Topic:

M&A

Latest Headlines

Latest Headlines

No M&A? No problem, Actelion says as it rolls out $160K-plus Uptravi

Actelion predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work thanks to its hefty price tag on new pulmonary arterial hypertension med Uptravi, execs said Tuesday.

UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson

Last week, Valeant CEO J. Michael Pearson, in the hospital with severe pneumonia, took a medical leave of absence. And now, the company is reportedly putting a new chief in his place.

At $48 per share, is Baxalta Shire's best potential move?

It looks like Baxalta and Shire may be the first to keep pharma's red-hot M&A streak going in 2016, with a deal between the two rumored for as early as this week. But not everyone's convinced it's the right move.

Activist investor nominates trio to HeartWare board to block Valtech buy

Engaged Capital first voiced its opposition to the HeartWare purchase of Valtech Cardio for about $930 million in cash and stock last October. Now, it's taking a step it had threatened earlier and nominated three board members. Success on that front would give the activist investor considerable leverage on the board, which currently is comprised of 8 members.

Baxalta reportedly warms up to Shire's $32B pitch, despite an 11th-hour licensing deal

Shire and Baxalta are getting close to a blockbuster merger, according to reports, circling a $32 billion deal after months of public squabbling over price.

Think we've seen the last of pharma's M&A tidal wave? Think again

If you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're expecting even more deal activity next year.

M&A: Buckle your seat belts for another big round of deals

With valuations down, buyouts and licensing deals become even more attractive. They're already a requirement. Anyone with a casual acquaintance with the state of Big Pharma R&D knows the giants in this business badly need promising mid- and late-stage assets to feed into their pipelines.

Italian orthopedic implant maker Lima trades hands from one investor to another

Earlier this year, Lima bought European rights to the Zuk unicompartmental knee, now rebranded as Physica Zuk, and the Discovery Total Elbow system from Zimmer as part of its merger with Biomet. It also gained rights to Biomet's Vanguard Complete Knee System in a couple of European countries. The terms of that deal were undisclosed.

Small-cap CryoLife to snap up mechanical heart valve startup for $130M

CryoLife is slated to buy Austin, TX-based startup On-X Life Technologies for $130 million in cash and stock. The Atlanta, GA-based acquirer specializes in tissue implants and medical devices for cardiac and vascular surgical use; the deal will add the On-X aortic valve as well as other marketed valve products.

Shire inches closer to Baxalta buy with cash-sweetened bid

Shire has offered up a new bid for elusive target Baxalta that's more or less what the Illinois drugmaker has been looking for, reports say. But that doesn't mean Baxalta isn't exploring its other options.
'